# Characterization of individuals fulfilling clinical criteria for limbic‐predominant age‐related TDP43 encephalopathy (LATE) in a tertiary memory clinic

## TL;DR

This study applies new criteria to identify LATE in dementia patients, showing distinct cognitive and brain atrophy patterns compared to Alzheimer's disease.

## Contribution

The study validates new clinical criteria for LATE and demonstrates distinct clinical and biological trajectories compared to Alzheimer's disease.

## Key findings

- Probable LATE showed slower cognitive decline and lower mortality rates compared to Alzheimer's disease.
- Probable LATE had lower hippocampal volumes and slower whole-brain atrophy compared to Alzheimer's disease.
- Possible LATE-AD showed faster cognitive decline and higher mortality rates compared to Alzheimer's disease.

## Abstract

Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) clinically mimics and often co‐occurs with Alzheimer's disease (AD). Expert consensus criteria have been proposed for the LATE clinical diagnosis, integrating clinical and radiological features, and AD biomarkers. Here, we applied the newly proposed criteria in a tertiary memory clinic population.

We included participants from the Amsterdam Dementia Cohort aged >50 years who received a diagnosis of MCI or dementia between 1997‐2024. Following the LATE consensus criteria scheme (Figure 1), we categorized participants as “Probable LATE”, “Possible LATE” or “Possible LATE‐AD” (i.e. LATE clinical and radiological profile with AD biomarker profile). Participants not fulfilling criteria for LATE but fulfilling NIA‐AA criteria for AD were categorized as AD. We compared the LATE groups with AD on cognitive decline (N = 1046, N Mean time=2.7[1.8] years) and atrophy (N = 208, Mean time=2.1[1.6]) using linear‐mixed effects models, and on mortality rates using Cox proportional hazard models.

Of the 3367 individuals, 1920 were classified into one of the four groups. Fifty‐one (1.5%) were classified as Probable LATE, 102 (3.0%) as Possible LATE, 122 (3.6%) as Possible LATE‐AD, and 1645 (48.8%) as AD (Table 1). Compared to AD, Probable LATE showed an attenuated cognitive decline (b[SE] for MMSE=0.12[0.05], p = 0.02) and lower mortality rates (HR[95% CI]=0.75[0.58‐0.95], p = 0.02), while individuals with Possible LATE‐AD had faster cognitive decline (b for MMSE=‐0.12[0.05], p = 0.01) and higher mortality rates (HR=1.55[1.25‐1.92], p <0.001, Figure 2). Compared to AD, Probable LATE had, at baseline, lower hippocampal volumes (b=‐0.83[0.27], p <0.01), and higher inferior‐temporal to hippocampal volume ratios (b=0.81[0.27], p <0.01). Furthermore, in Probable LATE, atrophy in a whole‐brain region‐of‐interest was slower compared to AD (b=0.14[0.08], p = 0.04). Possible LATE‐AD had, at baseline, thinner whole‐brain cortex (b=‐0.69[0.30], p = 0.02), lower hippocampal volumes (b=‐1.54[0.31], p <0.01), and higher inferior‐temporal to hippocampal volume ratios (b=1.73[0.30], p <0.01) than AD, but there was no difference in atrophy rates between Possible LATE‐AD and the other groups (Figure 3).

In a tertiary memory clinic population, the newly proposed clinical LATE criteria reveal clinical and atrophy trajectories that are distinct from AD, especially for Probable LATE and Possible LATE‐AD. Differential clinical and biological disease trajectories highlight the relevance of the LATE classification for diagnostic and prognostic purposes